Rafael Holdings completes Phase 3 TransportNPC trial for Trappsol Cyclo

Rafael Holdings announced completion of its pivotal Phase 3 TransportNPC study evaluating Trappsol Cyclo for Niemann-Pick Disease Type C treatment, with 94 patients across 27 sites. The company expects to submit an NDA to the FDA in the second half of 2026, positioning the company toward commercial-stage biotechnology operations in a high-unmet-need market.